The 340B Drug Program was created by Congress in 1992 and requires pharmaceutical manufacturers to provide outpatient drugs to eligible hospitals at significantly reduced prices. The program’s primary focus is to enable hospitals to stretch their resources and reinvest the savings into expanding services for underserved communities. 

Savings from the 340B program help Nebraska hospitals provide more comprehensive care for under-served patients across the state. 340B savings also help hospitals lower prescription drug costs for eligible patients and invest in community wellness and health. 

Benefits of the program include pharmaceutical discounts, improved patient access, and positive community health impacts. 

However, reforms proposed in Congress would force Nebraska’s hospitals to cut services, thereby limiting, or eliminating, these benefits to Nebraska’s most vulnerable patients. 

Such adverse impacts would be felt across the state and impact urban, suburban, and rural providers throughout all three congressional districts. 

87% of qualified Nebraska hospitals have already had a decrease in 340B revenue due to pharmaceutical manufacturers restricting 340B drugs through contract pharmacies.

340B is an essential program to hospitals providing care to vulnerable, underserved Nebraskans. It is paid for with drug discounts from manufacturers, not federal or state tax dollars.

Nebraska’s nonprofit 340B eligible hospitals work tirelessly to provide the best possible care to all Nebraskans, and we hope you can see the positive impacts the 340B program is having across the state.